Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Harini Burri"'
Autor:
Shringi Sharma, Xavier Pepin, Harini Burri, Lianqing Zheng, Nataliya Kuptsova‐Clarkson, Anouk de Jong, Ting Yu, Holly L. MacArthur, Michal Majewski, John C. Byrd, Richard R. Furman, Joseph A. Ware, James Mann, David Ramies, Veerendra Munugalavadla, Louise Sheridan, Helen Tomkinson
Publikováno v:
Clinical pharmacology in drug development. 11(11)
Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor approved to treat adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or previously treated mantle cell lymphoma. As the bioavailability of the acalabrutinib capsule (AC) dep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b6e46c90a33cd70426b4e64819bbb3a
https://pubmed.ncbi.nlm.nih.gov/36029150
https://pubmed.ncbi.nlm.nih.gov/36029150
Autor:
James Mann, Nataliya Kuptsova-Clarkson, Holly L MacArthur, Shringi Sharma, David Ramies, Michal Majewski, Anouk de Jong, Veerendra Munugalavadla, Harini Burri, Helen Tomkinson, Xavier Pepin, Lianqing Zheng, Joseph Ware, Ting Yu, Louise Sheridan
Publikováno v:
Blood. 138:4365-4365
Introduction: Acalabrutinib (Calquence ®), a selective Bruton tyrosine kinase (BTK) inhibitor, is approved for the treatment of mantle cell lymphoma (relapsed/refractory) and chronic lymphocytic leukemia. Patients with hematologic malignancies may r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e37847b29d3c57c97b09f32c0a8de011
https://doi.org/10.1182/blood-2021-146610
https://doi.org/10.1182/blood-2021-146610
Autor:
David G. Breckenridge, Harini Burri, Saritha Kusam, Archana Vijayakumar, Jamie Bates, David Hollenback
Publikováno v:
Journal of Hepatology. 70:e520-e521
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f08910071a8fd39e0e59f81d832073e8
https://doi.org/10.1016/s0618-8278(19)31029-1
https://doi.org/10.1016/s0618-8278(19)31029-1